###begin article-title 0
Combined kinase inhibition modulates parkin inactivation
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
Mutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunction may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise function remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphorylation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this post-translational modification for parkin function has remained unclear. Here we report that compound phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphorylation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent novel combinatorial therapeutic targets for treating PD.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C1">1</xref>
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C3">3</xref>
###xml 417 418 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C4">4</xref>
Parkinson disease (PD) is a progressive and substantially disabling neurodegenerative disorder (1-3). Its clinical symptoms primarily result from the progressive and rather selective degeneration of dopaminergic neurons of the substantia nigra pars compacta. Besides cell death, a pathological hallmark of PD in surviving neurons comprises Lewy bodies, ubiquitylated intraneuronal inclusions rich in alpha-synuclein (4).
###end p 4
###begin p 5
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C5">5</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C6">6</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C7">7</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C8">8</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C9">9</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C10">10</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C11">11</xref>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C12">12</xref>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
Even though largely a sporadic disorder, there are several genes associated with inherited forms of PD. One commonly implicated is PARK2, the gene encoding for parkin (5). Indeed, mutations in the parkin gene are responsible for a large percentage of autosomal-recessive, juvenile-onset parkinsonism (6,7). A variety of homozygous and compound heterozygous mutations have been reported, and although mutations that reduce but do not abolish parkin function are accompanied by dopaminergic cell loss in the presence of Lewy bodies (8,9), homozygous loss-of-function parkin mutations seem to be associated with a lack of Lewy bodies (10), raising the possibility that parkin may be involved in Lewy body biogenesis. Furthermore, parkin may also play a role in sporadic PD, given that it is present in Lewy bodies from sporadic PD patients (11,12).
###end p 5
###begin p 6
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C13">13</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C14">14</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C16">16</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C17">17</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C18">18</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C19">19</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C20">20</xref>
Parkin functions as an E3 ubiquitin ligase (13), and inactivation of its catalytic activity may lead to dopaminergic cell death due to the accumulation of toxic substrate protein(s). Recent studies suggest that changes in parkin solubility comprise a major mechanism of parkin inactivation both in familial and sporadic PD. For example, a wide range of pathogenic parkin point mutations result in decreased parkin solubility and promote its aggregation (14-16). In addition, an array of oxidative stressors (17), as well as direct post-translational parkin modifications, including dopamine modification (18) or S-nitrosylation (19,20), lead to dramatic changes in the solubility of parkin, thereby highlighting a mechanism for parkin dysfunction in the pathogenesis of idiopathic PD.
###end p 6
###begin p 7
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C21">21</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C22">22</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C23">23</xref>
Protein phosphorylation is another post-translational modification which has recently been linked to mechanism(s) underlying PD (e.g. 21). As protein kinases are tractable drug targets, these findings may help in the design of novel therapeutic strategies. Parkin has been previously described to be subject to phosphorylation by casein kinase I or by cyclin-dependent kinase 5 (cdk5), with modest changes in its enzymatic E3 ubiquitin ligase activity in either case (22,23). Given that compound or hyperphosphorylation of proteins can have profound effects on their aggregative properties, we sought to determine whether compound phosphorylation of parkin may modulate its aggregative properties. We hypothesized that such phosphorylation-induced changes could contribute directly to the inactivation of parkin and concomitantly reduced survival of dopaminergic neurons in PD.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Compound phosphorylation of parkin in vitro and in cells
###end title 9
###begin p 10
###xml 21 29 21 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 272 280 272 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C22">22</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C22">22</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 789 797 789 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 833 841 833 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F1">1</xref>
###xml 1005 1012 1005 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 126 131 <span type="species:ncbi:9606">human</span>
We first carried out in vitro phosphorylation experiments using a set of purified protein kinases and recombinant full-length human parkin protein, or select domains thereof (Fig. 1A and B). Purified full-length parkin displayed both mono- and polyubiquitylation activity in vitro (Fig. 1C) and was phosphorylated by casein kinase I (Fig. 1D-F), as previously reported (22). Site-directed mutagenesis using full-length parkin as well as parkin fragments confirmed that S101 and S378 were phosphorylation sites for casein kinase I (22), and an additional site was identified as S127 (Fig. 1D and E). Indeed, mutations of these three serine residues to alanines almost completely abrogated phosphorylation, indicating that these sites are the major phosphorylation sites for casein kinase I in vitro (Fig. 1D and F). Parkin was not an in vitro substrate for a series of other protein kinases analyzed here (Fig. 1G), indicating that only certain signal transduction cascades may impact upon parkin function in vivo.
###end p 10
###begin p 11
###xml 42 50 42 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 264 272 264 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 298 299 298 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 651 652 651 652 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 726 734 726 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1121 1122 1121 1122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1226 1227 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1240 1241 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1254 1255 1254 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1268 1269 1268 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1294 1295 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1320 1328 1320 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1619 1620 1617 1618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1730 1731 1728 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1744 1745 1742 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1764 1765 1762 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1789 1797 1787 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1930 1931 1926 1927 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2056 2057 2052 2053 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 2112 2120 2108 2116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2215 2223 2211 2219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2300 2302 2296 2298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2545 2553 2538 2546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Parkin phosphorylation by casein kinase I in vitro. (A) Schematic representation of parkin domain structure, with domain boundaries shown by amino acid residue numbers above, and of recombinant parkin domain combinations (full-length, N1-N3 and C1-C3) analyzed by in vitro phosphorylation assays. (B) The different recombinant parkin domains were purified as described in Materials and Methods, and analyzed for purity by SDS-PAGE and Coomassie staining. Full-length recombinant parkin as well as N1 and C3 truncated forms are indicated by arrows. Bacterial hsp70 (arrowhead), as determined by mass spectroscopy, co-purified with full-length parkin. (C) Full-length recombinant parkin was catalytically active, as assessed by in vitro autoubiquitylation in the presence of wild-type ubiquitin (Ub) or a lysine-less derivative (LL-Ub) lacking the conjugation sites necessary for polyubiquitylation. When the reaction was performed with LL-Ub, lower levels of ubiquitylation were detected, indicating that recombinant parkin displays both multiple monoubiquitylation as well as polyubiquitylation activity towards itself. (D) Full-length recombinant parkin (wt), or equal amounts of the indicated point-mutated versions (S101A, n = 4; S127A, n = 4; S131A, n = 4; S378A, n = 4; S101A/S127A/S378A, n = 3), were subjected to in vitro phosphorylation reactions using casein kinase I, and phosphate incorporation quantified by using a PhosphorImager (mean+/-S.E.M.). Note that the S101A mutant displayed increased phosphate incorporation in the context of the full-length protein, possibly reflecting conformational effects. (E) The N1 fragment of recombinant parkin (wt) or equal amounts of the indicated point-mutated versions (S101A, n = 6; S127A, n = 4; S101A/S127A, n = 2) were subjected to in vitro phosphorylation reactions using casein kinase I, and phosphate incorporation quantified by using a PhosphorImager (mean+/-S.E.M.). (F) Example of a phosphorylation experiment using full-length recombinant parkin (wt) or the triple mutant S101A/S127A/S378A. (G) Parkin phosphorylation by additional protein kinases in vitro. Full-length recombinant parkin or glutathione S-transferase-parkin (arrows) was subjected to in vitro phosphorylation reactions using cAMP-dependent protein kinase (PKA), PKC, Ca2+/calmodulin-dependent protein kinase II (CaM kinase II), GSK3beta or ASK-1, as indicated, using various proteins as positive controls (synapsin, tau or MBP, respectively) (arrowheads). None of these kinases significantly phosphorylated parkin in vitro.
###end p 11
###begin p 12
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F2">2</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F2">2</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C24">24</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C25">25</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F2">2</xref>
###xml 796 797 792 793 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 805 807 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C26">26</xref>
###xml 974 975 966 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 511 516 <span type="species:ncbi:9606">human</span>
To assess phosphorylation of parkin in cells, we generated phospho-state-specific antibodies against phospho-S101 and phospho-S378. Their phosphorylation-state-specificity was confirmed using recombinant, phosphorylated parkin protein in vitro. The antibodies only detected the protein when previously phosphorylated by casein kinase I, but not its non-phosphorylated form (Fig. 2A). Constitutive phosphorylation of parkin on both S101 and S378 was detected when HEK293T cells were transiently transfected with human parkin (Fig. 2B). Upon treatment of transfected cells with IC261, a selective inhibitor of casein kinase I (24,25), a significant decrease in the phosphorylation state of both S101 and S378 of parkin was detected (Fig. 2C). Similarly, treatment of transfected cells with 35 microm D4476 (26), a distinct, structurally non-related and potent inhibitor of casein kinase I led to a significant decrease in parkin phosphorylation (by 44 +/- 10%, mean+/-S.E.M., n = 3) in the absence of measurable cytotoxicity. Together, these data indicate that S101 and S378 of parkin are phosphorylated by casein kinase I in intact cells as well.
###end p 12
###begin p 13
###xml 102 103 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 261 269 261 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 392 393 392 393 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 568 569 568 569 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 652 653 652 653 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 773 774 769 770 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 665 670 <span type="species:ncbi:9606">human</span>
Parkin phosphorylation by casein kinase I in cells assessed using phospho-state-specific antibodies. (A) Phospho-state-specific antibodies against phospho-S101 (P-Ser101) or against phospho-S378 (P-Ser378) recognize recombinant full-length parkin only upon its in vitro phosphorylation by casein kinase I (+CK1), but not if the protein is not previously subjected to phosphorylation (-CK1). (B) Exogenous human parkin, upon transfection in HEK293T cells (+transf.), is constitutively phosphorylated on both S101 and S378 residues. Cells were treated for 1 h with 500 nm okadaic acid before cell lysis to stabilize the phosphorylation state of parkin. (C) Exogenous human parkin phosphorylation on S101 and S378 decreases upon treatment of HEK293T cells with IC261 (50 microm), a specific inhibitor of casein kinase I.
###end p 13
###begin p 14
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C23">23</xref>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 257 258 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 270 271 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
###xml 421 429 417 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 460 461 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 473 474 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
###xml 775 776 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
###xml 923 925 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C27">27</xref>
###xml 1024 1025 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1037 1038 1025 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
###xml 1183 1193 1171 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vice versa</italic>
###xml 1200 1201 1188 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
Apart from casein kinase I, parkin is also subject to phosphorylation by cdk5 on S131 (23). A phospho-mimetic mutant on this site displayed enhanced casein kinase I-mediated phosphorylation when compared with wild-type in vitro (307 +/- 12%; mean+/-S.E.M., n = 5) (Fig. 3A). Conversely, a phospho-mimetic mutant on all three casein kinase I sites served as a better substrate for cdk5 when compared with wild-type parkin in vitro (540 +/- 240%; mean+/-S.E.M., n = 3) (Fig. 3B). Similar findings were observed in parkin-transfected HEK293T cells using phospho-state-specific antibodies. On the one hand, an S131E parkin mutant, which mimicks constitutive phosphorylation by cdk5, displayed enhanced phosphorylation by casein kinase I when compared with wild-type parkin (Fig. 3C). On the other hand, blocking the activity of cdk5 by treating transfected HEK293T cells with roscovitine, a highly specific inhibitor for cdk5 (27), decreased phosphorylation on the casein kinase I sites of parkin (to 47 +/- 10%; mean+/-S.E.M., n = 4) (Fig. 3D). Together, these data indicate that phosphorylation of parkin by cdk5 enhances its propensity to serve as a substrate for casein kinase I and vice versa (Fig. 3E).
###end p 14
###begin p 15
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 76 84 76 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 239 240 239 240 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 510 511 510 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 708 709 708 709 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 793 794 789 790 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 919 920 915 916 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
Compound phosphorylation of parkin in vitro and in cells. (A) Example of an in vitro phosphorylation experiment using full-length recombinant parkin (wt), or the indicated point-mutated versions (S131A, S131E), and casein kinase I (CK1). (B) Example of an in vitro phosphorylation experiment using full-length recombinant parkin (wt), or the indicated point-mutated versions (S101A/S127A/S378A, S101E/S127E/S378E), and cdk5. Arrows, full-length parkin and mutant versions thereof; arrowhead, bacterial hsp70. (C) HEK293T cells were transfected with either wild-type (wt) or S131E-mutant parkin, and equal amounts of cell extracts analyzed for parkin phosphorylation using phospho-state-specific antibodies. (D) Parkin-transfected HEK293T cells were treated with or without roscovitine (1 microm) for 12 h, and equal amounts of cell extracts analyzed for parkin phosphorylation using phospho-state-specific antibodies. (E) Schematic model depicting how parkin phosphorylation by one kinase may increase its propensity to serve as a substrate for the other kinase, thereby leading to a multiple-phosphorylated state.
###end p 15
###begin title 16
Effects of parkin phosphorylation on activity and inclusion formation
###end title 16
###begin p 17
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C23">23</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 903 904 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 1181 1182 1181 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 1371 1372 1371 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
###xml 1607 1608 1607 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F4">4</xref>
Phosphorylation of parkin may regulate its E3 ubiquitin ligase activity or modulate its insolubility, with downstream effects on dopaminergic cell survival in either case. To determine whether phosphorylation of parkin would affect its catalytic activity, we performed autoubiquitylation assays in vitro using various phospho-mimetic mutants (Fig. 4). A parkin phospho-mimetic mutant for cdk5 phosphorylation (131E) displayed ubiquitylation activity similar to wild-type, whereas its non-phosphorylatable counterpart (131A) was slightly more active, as previously described (23) (Fig. 4A). Parkin phospho-mimetic mutants for the individual casein kinase I sites (101E or 378E) displayed ubiquitylation activity similar to wild-type (Fig. 4B-D). Similarly, a phospho-mimetic mutant for all three casein kinase I sites (101E/127E/378E) did not display significant changes in ubiquitylation activity (Fig. 4E-G), indicating that neither mimicking individual nor combined phosphorylation of the casein kinase I sites affect parkin's ubiquitylation activity. A phospho-mimetic mutant for the adjacent casein kinase I and cdk5 sites (127E/131E) did not display changes in activity (Fig. 4C and D), whereas a phospho-mimetic mutant for compound phosphorylation by both casein kinase I and cdk5 (101E/127E/131E/378E) displayed slightly enhanced autoubiquitylation activity (Fig. 4E-G). However, this modest enhancement was also observed for the respective non-phosphorylatable mutant counterpart (101A/127A/131A/378A), and therefore does not seem to reflect specific effects related to parkin phosphorylation (Fig. 4E-G).
###end p 17
###begin p 18
###xml 85 86 85 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 240 241 240 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 492 493 492 493 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 978 979 976 977 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1470 1471 1466 1467 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1783 1784 1779 1780 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1868 1869 1864 1865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1881 1882 1877 1878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1893 1894 1889 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1905 1906 1901 1902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1922 1923 1918 1919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1939 1940 1935 1936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2180 2181 2174 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2191 2192 2185 2186 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 2275 2276 2269 2270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2287 2288 2281 2282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2304 2305 2298 2299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2321 2322 2315 2316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Phosphomimetic parkin mutants do not display drastic changes in E3 ligase activity. (A) Example of an autoubiquitylation experiment using wild-type, 131A-mutant or 131E-mutant parkin forms, displaying enhanced activity of the 131A-mutant. (B) Example of an autoubiquitylation experiment using wild-type, 378A-mutant or 378E-mutant parkin forms and either using ubiquitin (Ub) or a lysine-less derivative (LL-Ub) to assess polyubiquitylation versus monoubiquitylation activity, respectively. (C) Quantification of experiments of the type depicted in (B), indicating that the individual mutants do not lead to significant changes in the ubiquitylation activity of parkin. The ubiquitin-positive ladder obtained with various parkin-mutant proteins and wild-type ubiquitin was quantified, values were corrected for differences in protein input as analyzed separately using an anti-parkin antibody (844) and normalized to the activity of wild-type parkin. Bars depict mean+/-S.E.M. (D) Quantification of experiments of the type depicted in (B), indicating that the individual mutants do not lead to significant changes in the monoubiquitylation activity of parkin. The ubiquitin-positive ladder obtained with various parkin-mutant proteins and lysine-less ubiquitin, reflecting multiple mono-ubiquitylation activity, was quantified, corrected for differences in protein input and normalized to the activity of wild-type parkin. Bars depict mean+/-S.E.M. N.A., not analyzed. (E) Example of an autoubiquitylation experiment using wild-type or the indicated parkin mutants (AAA, 101A/127A/378A; EEE, 101E/127E/378E; 131A-AAA, 101A/127A/131A/378A; 131E-EEE, 101E/127E/131E/378E), and either wild-type ubiquitin (Ub) of a lysine-less derivative (LL-Ub) to assess monoubiquitylation activity. (F) The ubiquitin-positive ladder obtained with various parkin-mutant proteins (131E, n = 3; 131A, n = 2; AAA, n = 3; EEE, n = 3; 131A-AAA, n = 4; 131E-EEE, n = 4) and wild-type ubiquitin was quantified. Values were corrected for differences in protein input as analyzed separately using an anti-parkin antibody (844), and normalized to the activity of wild-type parkin. Bars depict mean+/-S.E.M. *P < 0.05. (G) The ubiquitin-positive ladder obtained with various parkin mutant proteins (AAA, n = 3; EEE, n = 3; 131A-AAA, n = 4; 131E-EEE, n = 4) and lysine-less ubiquitin, reflecting multiple mono-ubiquitylation activity, was quantified, corrected for differences in protein input and normalized to the activity of wild-type parkin. Bars depict mean+/-S.E.M. Error bars are only depicted when larger than column lines. The 131A-AAA and 131E-EEE mutants displayed a significant increase in autoubiquitylation activity only as assessed using ubiquitin, but not lysine-less ubiquitin.
###end p 18
###begin p 19
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 955 956 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1114 1115 1110 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 1237 1238 1233 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 1328 1329 1324 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
We next addressed whether parkin phosphorylation may modulate its tendency to form inclusions in cell culture and concomitantly alter its solubility in detergent. For this purpose, HEK293T cells were transfected with parkin or various phospho-mimetic or non-phosphorylatable mutants, treated with the proteasome inhibitor MG-132, and the amount of parkin inclusion bodies determined by immunocytochemistry (Fig. 5A). Wild-type and all mutant parkin proteins were overexpressed to similar degrees (Fig. 5B), and the parkin mutant mimicking phosphorylation by only casein kinase I (101E/127E/378E) or by only cdk5 (131E) did not show a significant increase in the number of parkin inclusion bodies when compared with wild-type (Fig. 5C). These results indicate that individually mimicking phosphorylation by either casein kinase I or by cdk5 does not lead to changes in parkin aggregation. In contrast, a pronounced, 6.2 +/- 2-fold increase (mean+/-S.E.M., n = 4) in cells with parkin inclusions was found with the parkin mutant mimicking compound phosphorylation by both protein kinases (101E/127E/131E/378E) (Fig. 5C). Such enhanced aggregation was not observed with a non-phosphorylatable mutant counterpart (101A/127A/131A/378A) (Fig. 5C) and was only observed when mimicking phosphorylation on all four serine residues (Fig. 5D), indicating that it was specific for mimicking compound phosphorylation of parkin by both casein kinase I and cdk5.
###end p 19
###begin p 20
###xml 84 85 84 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 182 183 178 179 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 338 339 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 753 754 741 742 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 854 855 838 839 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1244 1245 1228 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1257 1258 1241 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1269 1270 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1281 1282 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1298 1299 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1315 1316 1299 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1350 1351 1332 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1421 1422 1403 1404 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1522 1523 1500 1501 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1878 1879 1854 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1887 1888 1863 1864 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1998 1999 1970 1971 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2210 2211 2182 2183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2418 2419 2388 2389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Phospho-mimetic parkin mutants display profound changes in aggregative properties. (A) HEK293T cells were transfected with 101E/127E/131E/378E-mutant parkin, and treated with 5 microm MG-132 for 12 h prior to immunocytochemistry using a polyclonal anti-parkin antibody (844) (green). Nuclei were stained with DAPI. Scale bar, 10 microm. (B) To assure equal levels of overexpression of wild-type and mutant parkin forms, cells were transfected with the various forms as indicated and 50 microg of cell extracts were subjected to western blot analysis 72 h later using an anti-parkin antibody (Abcam) or an anti-tubulin antibody to correct for differences in protein loading. Wild-type and mutant parkin constructs were overexpressed to similar degrees. (C) HEK293T cells were transfected with wild-type parkin or various mutant forms, treated with 5 microm MG-132 for 12 h followed by immunocytochemistry as described above. The percent of transfected cells displaying large perinuclear inclusions was determined by an investigator unaware of treatment groups, and the data plotted as an overall fold-increase in the number of transfected cells displaying large perinuclear inclusions when compared with wild-type parkin-expressing cells (131E; n = 3; 131A; n = 3; AAA, n = 3; EEE, n = 4; 131A-AAA, n = 4; 131E-EEE; n = 4). Bars depict mean+/-S.E.M. *P < 0.05. Error bars are only depicted when larger than column lines. (D) HEK293T cells were transfected with wild-type parkin or various mutant forms, treated with 5 microm MG-132 for 12 h followed by immunocytochemistry. None of the combinations analyzed led to significant changes in the number of transfected cells with inclusions, indicating that only the quadruple mutant parkin-variant mimicking compound phosphorylation by casein kinase I and cdk5 displays an increased tendency to aggregate. Bars depict mean+/-S.E.M. (n = 3). (E) Analysis of the distribution of overexpressed wild-type (wt) or mutant parkin variants (treated with 5 microm MG-132 for 12 h before analysis) (total, T) in the Triton X-100-soluble (S) and insoluble pellet (P) fractions of HEK293T extracts upon blotting with an anti-parkin antibody (Abcam) or an anti-actin antibody. (F) Quantification of experiments of the type depicted in (E), where the amount of protein in the supernatant, when compared with that in the pellet, is plotted as % soluble parkin. Bars depict mean+/-S.E.M. (n = 3).
###end p 20
###begin p 21
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C14">14</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C18">18</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
###xml 675 676 675 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F5">5</xref>
An increased propensity of parkin to be confined to intracellular aggregates should result in changes in its detergent extractability, as previously described for several pathogenic parkin mutants and stress-induced parkin alterations (14-18). Indeed, although a significant amount of wild-type parkin was found in the Triton-soluble fraction in the presence of MG-132, the quadruple mutant mimicking compound phosphorylation displayed decreased solubility (Fig. 5E and F). In contrast, no change in detergent extractability was observed for the non-phosphorylatable mutant counterpart, which was present in the soluble fraction to a degree similar to wild-type parkin (Fig. 5E and F). Together, these data suggest that simultaneous phosphorylation of parkin on both casein kinase I and cdk5 sites profoundly facilitates its aggregation into inclusion bodies.
###end p 21
###begin title 22
Increased phospho-parkin in Parkinson brain
###end title 22
###begin p 23
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C28">28</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C29">29</xref>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C28">28</xref>
###xml 1244 1245 1244 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 1317 1319 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C27">27</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 311 318 <span type="species:ncbi:9606">patient</span>
To determine whether parkin undergoes phosphorylation in human brain, and in sporadic PD, we chose to analyze parkin and phospho-parkin levels from distinct brain areas reported to be differentially affected by disease pathology (28). Samples from three distinct brain areas were available from each individual patient, and control and PD cases matched for postmortem interval, tissue-handling and storage conditions as important variables in these comparisons (Fig. 6A). The levels of total parkin were similar in caudate, cortex and cerebellum (Fig. 6B), and there were no differences in the levels of total parkin between control and PD cases in any of the three brain regions analyzed (Fig. 6C and D), as previously described for cortical samples (29). However, we found statistically significant increases in phospho-Ser101 parkin levels in PD versus control cases (Fig. 6C and D). These increases were detected in the caudate, known to be particularly affected by the presence of Lewy bodies and Lewy neurites during relatively early stages of disease development (28). No significant changes in phospho-parkin levels in PD versus control cases were observed in the cortex, and no phospho-parkin could be detected in the cerebellum (Fig. 6C and D), a brain area largely devoid of Lewy bodies and Lewy neurites (27). Together, these data demonstrate a neuroanatomical and disease-specific alteration in the phosphorylation status of parkin.
###end p 23
###begin p 24
###xml 89 90 89 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 197 198 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 482 483 468 469 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 846 847 832 833 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 952 953 938 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 975 976 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1047 1048 1031 1032 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1283 1284 1255 1256 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1400 1401 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 347 354 <span type="species:ncbi:9606">patient</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
###xml 1222 1230 <span type="species:ncbi:9606">patients</span>
Selective increase in phospho-parkin and p25 in distinct areas of idiopathic PD brains. (A) Gender, age at death (years) and postmortem interval (PMI, h) for the eight human brains analyzed here. (B) Relative levels of total parkin, casein kinase I isoforms alpha, delta and epsilon, cdk5, p35 and p25 in three distinct brain areas from a control patient, and of tubulin as a protein loading control. *Overexposed blot shows the absence of detectable p25 levels in the cerebellum. (C) Levels of phospho-parkin (P-Ser101), parkin, p35/p25 and tubulin as a protein loading control were analyzed in caudate, cortex and cerebellum from four control and four PD patients which were matched for postmortem interval tissue collection. Arrows indicate parkin band, arrowheads indicate cross-reacting band detected with the anti-parkin antibody (Abcam). (D) Levels of phospho-parkin, parkin and p25 were normalized to tubulin levels and plotted on a histogram (n = 4; mean+/-S.E.M., *P < 0.05). Error bars are only depicted when larger than column lines. (E) Levels of casein kinase Iepsilon (CK1epsilon), cdk5 and tubulin as a protein loading control were analyzed in caudate, cortex and cerebellum from four controls and four PD patients matched for postmortem interval tissue collection. (F) Levels of CK1alpha, delta and epsilon, cdk5 and p35 were normalized to tubulin levels and plotted on a histogram (n = 4; mean+/-S.E.M.). Error bars are only depicted when larger than column lines.
###end p 24
###begin p 25
###xml 520 522 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C30">30</xref>
###xml 530 531 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 729 731 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C31">31</xref>
###xml 787 788 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 950 951 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
###xml 1113 1114 1085 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F6">6</xref>
As a first step towards identifying the possible underlying mechanism(s) for the differences in phospho-parkin levels in PD when compared with control brains, we analyzed the total levels of casein kinase I alpha, delta and epsilon, as well as of cdk5 and its activator p25/p35. Similar levels of the alpha and epsilon isoforms of casein kinase I were detected in all three brain areas, whereas the levels of the delta isoform were lower in the cerebellum when compared with caudate and cortex, as previously described (30) (Fig. 6B). Similar levels of cdk5 were detected in all three brain areas, but the levels of p35 were lower in the cerebellum when compared with caudate and cortex, as previously described in rodent brain (31), and no p25 could be detected in the cerebellum (Fig. 6B). No differences were observed in the levels of the three casein kinase isoforms or of cdk5 in PD versus control in any of the three brain areas analyzed (Fig. 6E and F). However, the total levels of p25 were significantly higher in PD when compared with control samples in the caudate, with no changes in the cortex (Fig. 6C and D). Thus, the observed increase in phospho-parkin levels in PD when compared with control may, at least in part, be due to changes in the total levels of p25 in the distinct brain areas analyzed, with concomitant changes in cdk5 activity followed by compound parkin phosphorylation and aggregation.
###end p 25
###begin title 26
Modulation of mutant parkin aggregation by a combination of kinase inhibitors
###end title 26
###begin p 27
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C14">14</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C16">16</xref>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F7">7</xref>
###xml 793 794 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F7">7</xref>
###xml 861 869 861 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F7">7</xref>
###xml 1145 1146 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F7">7</xref>
As increased parkin phosphorylation seems to correlate with sporadic PD in vivo and enhances the aggregative properties of parkin in cultured cells, inhibiting casein kinase I and cdk5 activities may have beneficial effects in preventing such protein aggregation. To address this possibility, we quantified the number of aggregates in cells transfected with three pathogenic parkin mutants (R256C, R275W, C289G) previously described to display enhanced aggregative properties when compared with wild-type parkin (14-16). Indeed, all three mutants showed an enhanced propensity to form intracellular aggregates in the absence of proteasome inhibition, with C289G>R275W>R256C (Fig. 7A). These pathogenic mutants did not display significant differences in their autoubiquitylation activity (Fig. 7B) and were subject to phosphorylation by casein kinase I and cdk5 in vitro (Fig. 7C), indicating that their major pathogenic mechanism of action seems to involve enhanced aggregation. Concomitant with their reduced detergent extractability, we observed that they were present in the Triton-insoluble fraction in a heavily phosphorylated manner (Fig. 7D). Therefore, we next studied whether inhibiting casein kinase I and cdk5 activities may modulate the aggregative properties of these mutant proteins.
###end p 27
###begin p 28
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 251 252 249 250 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 421 422 419 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 435 443 433 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 613 614 611 612 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
Analysis of pathogenic parkin mutants. (A) The percentage of transfected cells displaying parkin aggregates using wild-type or various pathogenic parkin point mutants (wt, n = 5; R256C, n = 6; R275W, n = 11; C289G, n = 10). Bars depict mean+/-S.E.M. (B) Example of an autoubiquitylation experiment using wild-type or the indicated parkin mutants, and either wild-type ubiquitin (Ub) or a lysine-less derivative (LL-Ub). (C) Example of in vitro phosphorylation experiments using full-length recombinant parkin (wt), or the indicated point-mutated versions, and either casein kinase I (CK1, top) or cdk5 (bottom). (D) Analysis of the distribution of overexpressed wild-type (wt) or the various mutant parkin proteins (total, T) in the Triton X-100-soluble (S) and insoluble pellet (P) fractions of HEK293T extracts upon blotting with a phospho-state-specific parkin antibody (P-Ser378), an anti-parkin antibody (Abcam) or an anti-actin antibody. Note that the phosphorylation status of wild-type parkin in the soluble and insoluble fractions could only be detected in the presence of okadaic acid or upon prolonged exposure of the blot (not shown).
###end p 28
###begin p 29
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C32">32</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C24">24</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C25">25</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C25">25</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C26">26</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 951 959 951 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 966 967 966 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F3">3</xref>
###xml 1256 1257 1256 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 1441 1442 1441 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 1666 1667 1666 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F7">7</xref>
Cells were transfected with the aggregative R256C mutant and analyzed 72 h after transfection. Around 20% of transfected cells displayed large perinuclear inclusions, and treatment of cells during the last 12 h using two structurally dissimilar cdk5-specific inhibitors (roscovitine and GW8510 (32)), or two distinct casein kinase I-specific inhibitors (CKI-7 (24,25)) and D4476 (25,26)) profoundly decreased the number of cells with R256C-mutant parkin aggregates (Fig. 8A). Statistically significant additive effects in decreasing the number of cells with aggregates were observed when using combinations of a cdk5-specific and a casein kinase I-specific inhibitor (Fig. 8A), further indicating that the effects were specific for inhibiting the activity of these two protein kinases. The extent of the additive effect was relatively small, in agreement with the observed crosstalk between casein kinase I and cdk5 phosphorylation of parkin observed in vitro (Fig. 3). Compound inhibition of cdk5 and casein kinase I activities resulted in a roughly 70% decrease in the number of cells displaying aggregates for the R256C mutant, when compared with a 25% decrease for the R275W mutant, with no effects observed for the most aggregative C289G mutant (Fig. 8B). Addition of a casein kinase I-specific and a cdk5-specific inhibitor decreased the phosphorylation status of the three pathogenic parkin mutants analyzed to a similar degree (Fig. 8C and D), indicating that the relative efficiency by which compound kinase inhibition affects aggregation of the respective mutants is likely due to the observed distinct inherent aggregative properties of the mutants (Fig. 7A).
###end p 29
###begin p 30
###xml 75 76 75 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 339 340 335 336 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 361 362 353 354 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 381 382 369 370 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 405 406 389 390 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 436 437 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 601 602 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 611 612 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 788 789 766 767 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 811 812 785 786 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 827 828 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 841 842 815 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 855 856 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 890 891 862 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 901 902 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 972 973 944 945 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1142 1143 1110 1111 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1165 1166 1129 1130 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1372 1373 1336 1337 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1626 1627 1588 1589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1634 1637 1596 1599 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(E)</bold>
###xml 2002 2003 1960 1961 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2024 2025 1978 1979 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2043 2044 1993 1994 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2063 2064 2009 2010 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2087 2088 2029 2030 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2118 2119 2058 2059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2284 2285 2224 2225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2295 2296 2235 2236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 2538 2539 2474 2475 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2565 2566 2497 2498 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Inhibition of parkin phosphorylation decreases mutant parkin aggregation. (A) The percentage of transfected cells displaying R256C-mutant parkin aggregates were quantified in the absence (-) or presence of various kinase inhibitors, or combinations thereof, present for 12 h before fixation. Inhibitors used included roscovitine (0.5 microm), GW8510 (0.25 microm), CKI-7 (150 microm) and D4476 (17.5 microm). Bars depict mean+/-S.E.M. (n = 3). Statistically significant additive effects were observed when using a combination of kinase inhibitors, when compared with individual inhibitor treatments. *P < 0.1. (B) Quantification of the percentage of transfected cells displaying R256C-mutant, R275W-mutant or C289G-mutant parkin aggregates in the absence (-) or presence (+) of 0.25 microm GW8510 and 17.5 microm D4476 (R256C, n = 5; R275W, n = 3; C289G, n = 4). Bars depict mean+/-S.E.M. *P < 0.1; **P < 0.01. Error bars are only depicted when larger than column lines. (C) Analysis of the phosphorylation status of parkin in HEK293T cells transfected with wild-type (wt) or mutant parkin variants, treated without (-) or with (+) 0.25 microm GW8510 and 17.5 microm D4476 for 12 h before analysis upon blotting with the phospho-Ser378 antibody (*overexposed blot to show phosphorylation of wild-type parkin), an anti-parkin antibody (Abcam) or an anti-tubulin antibody. (D) Quantification of experiments of the type depicted in (C), where the amount of phospho-parkin in the presence of inhibitors, when compared with that in the absence of inhibitors, is plotted as % decrease in phosphorylation. Bars depict mean+/-S.E.M. (n = 3). (E) The percentage of transfected cells displaying C289G-mutant parkin aggregates (left) and the percentage of those cells displaying (at least) one large perinuclear aggregate (right) were quantified in the absence (-) or presence of various kinase inhibitors, or combinations thereof, present for 12 h before fixation. Inhibitors used included roscovitine (0.5 microm), GW8510 (0.25 microm), IC261 (25 microm), CKI-7 (150 microm) and D4476 (17.5 microm). Bars depict mean+/-S.E.M. (n = 3). Statistically significant additive effects were observed when using a combination of kinase inhibitors, when compared with individual inhibitor treatments. **P < 0.05. (F) The percentage of transfected cells displaying C289G-mutant parkin aggregates (left) and the percentage of those cells displaying (at least) one large perinuclear aggregate (right) were quantified in the absence (-) or presence of 0.5 microm roscovitine and 150 microm CKI-7. Inhibitors were added 12 h before fixation (12 h), 24 and 12 h before fixation (24 h) or 36, 24 and 12 h before fixation (36 h).
###end p 30
###begin p 31
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
###xml 1148 1149 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN407F8">8</xref>
As the C289G-parkin mutant accumulated in perinuclear aggregates in virtually all transfected cells (Fig. 8B), we reasoned that the effects of inhibiting parkin phosphorylation may be best studied by analyzing the size and number of aggregates for this potent aggregative parkin mutant. Indeed, although treatment of transfected cells during the last 12 h using distinct cdk5 inhibitors, casein kinase I inhibitors or a combination thereof did not decrease the number of cells with mutant parkin inclusions, we observed a decrease in the number of cells displaying a large perinuclear aggregate (Fig. 8E). The effects of individual inhibitor treatment were significant on its own, and statistically significant additive effects were observed when using a combination of both inhibitors, with a nearly 50% reduction in the number of cells with large perinuclear aggregates (Fig. 8E). In addition, prolonged and repetitive incubation of cells with a mixture of a cdk5-specific and a casein kinase I-specific inhibitor resulted in additive beneficial effects in decreasing the number of cells with large C289G-mutant parkin aggregates with time (Fig. 8F). Together, these data show that inhibiting compound phosphorylation of parkin can regulate its aggregative properties in culture, indicating that such treatment is useful in maintaining parkin's protective function in cultured cells.
###end p 31
###begin title 32
DISCUSSION
###end title 32
###begin p 33
###xml 140 148 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C33">33</xref>
Here, we report that parkin, a protein essential for the sustained survival of dopaminergic neurons, is subject to compound phosphorylation in vitro and in cultured cells. Such compound phosphorylation by casein kinase I and cdk5 enhances its insolubility, leading to aggregation and concomitant inactivation. Although phosphorylation does not change parkin's E3 ubiquitin ligase activity, increased aggregation effectively decreases the amount of soluble parkin protein able to exert a neuroprotective role (33). Notably, only simultaneous, but not individual phosphorylation by either casein kinase I or cdk5 seems to alter parkin solubility. Moreover, phosphorylation of parkin by one kinase seems to enhance its susceptibility to serve as a substrate for the other kinase. In this manner, simultaneous activation of both kinases may cooperatively contribute towards parkin inactivation.
###end p 33
###begin p 34
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C28">28</xref>
###xml 54 60 <span type="species:ncbi:9606">humans</span>
To assess whether parkin phosphorylation may occur in humans, we analyzed samples from caudate nucleus, cortex and cerebellum of control and PD brains. We observed enhanced parkin phosphorylation in PD when compared with control in the caudate, with no changes in the cortex. Of note, parkin phosphorylation could not be detected in the cerebellum in either control or PD samples. The neuroanatomical differences in parkin phosphorylation between control and sporadic PD samples correlate with the relative extent to which these distinct brain areas are affected by disease pathology (28), indicating that abnormal parkin phosphorylation and concomitant inactivation may contribute to neuronal degeneration in sporadic PD.
###end p 34
###begin p 35
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C34">34</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C35">35</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C36">36</xref>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C37">37</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C38">38</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C39">39</xref>
###xml 794 799 <span type="species:ncbi:10090">mouse</span>
We further examined whether the increase in parkin phosphorylation in PD brains may correlate with increases in the levels of cdk5, its activator p25/p35 or casein kinase I. Although we observed no changes in the levels of cdk5 or the levels of distinct casein kinase isoforms, we did find an increase in the levels of p25 in the caudate in PD when compared with control samples, with no changes in the cortex and the absence of detectable p25 in the cerebellum. In this context, it is interesting to note that p25 is known to lead to prolonged activation of cdk5 (34) and that cdk5 and p35 have been reported to accumulate in Lewy bodies in postmortem PD brains (35,36). Furthermore, an increase in cdk5 levels and activity has been observed in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD (37), and various neurotoxic insults induce generation of p25 from p35 (38), indicating that the activity of cdk5 may play a key role in the pathogenesis of sporadic PD (39).
###end p 35
###begin p 36
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C40">40</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C41">41</xref>
Little is known regarding de-regulation of casein kinase I activities during neurodegeneration (40), but most casein kinase I isoforms seem to be basally active (41). Our present data suggest that increased cdk5-mediated parkin phosphorylation would lead to a concomitant increase in casein kinase I-mediated phosphorylation events, as detected here using phospho-state-specific antibodies, thereby generating a compound phosphorylated protein with decreased solubility.
###end p 36
###begin p 37
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C42">42</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C43">43</xref>
Finally, the generally high basal casein kinase I and cdk5 activities suggest a very active role for protein phosphatases in controlling the steady-state levels of parkin phosphorylation. Indeed, a variety of studies indicate that inhibition of phosphatase activities, with concomitant hyperphosphorylation of proteins, can lead to PD-related neurodegeneration (42,43). Thus, a complex balance between kinase and phosphatase activities, possibly in a cell-type and region-specific manner, may be subject to acute and/or chronic regulation.
###end p 37
###begin p 38
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C14">14</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C16">16</xref>
To determine whether inhibition of casein kinase I and cdk5 activities would display beneficial effects in decreasing the aggregative properties of pathogenic parkin-mutant protein, we chose to analyze three distinct point mutants whose pathogenic mechanism of action seems to involve enhanced aggregation (14-16). Importantly, using a combination of inhibitors against casein kinase I and cdk5, we could decrease the number of cells displaying parkin aggregates for two out of three mutants tested (R256C and R275W). For the third point mutant (C289G), which displayed the most dramatic aggregative phenotype, combined kinase inhibition led to a decrease in the number of cells displaying large perinuclear aggregates, indicating beneficial effects of such inhibitor treatment in modulating the profound aggregation even of this pathogenic mutant.
###end p 38
###begin p 39
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C44">44</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C45">45</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C46">46</xref>
In conclusion, our experiments indicate that regulating the phosphorylation status of parkin has beneficial effects in reducing parkin aggregation and concomitant inactivation. Although future studies will be necessary to determine the neuroprotective or beneficial effects of combined kinase inhibition for PD subjects, the present results may have additional implications for other approaches in treating this neurodegenerative disorder, including gene replacement (44,45) or transplantation therapies (46).
###end p 39
###begin title 40
MATERIALS AND METHODS
###end title 40
###begin title 41
Plasmid construction
###end title 41
###begin p 42
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hin</italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C47">47</xref>
###xml 661 664 661 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 667 670 667 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xba</italic>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C48">48</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 353 358 <span type="species:ncbi:9606">human</span>
###xml 592 597 <span type="species:ncbi:9606">human</span>
###xml 703 707 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Human full-length parkin was amplified by PCR (primer sequences: 5'-TTA TGA ATT CAT ATA GTG TTT GTC AGG TTC AAC-3' and 5'-TTT AAA GCT TTT ACA CGT CGA ACC AGT GGT CCC-3') using a full-length piTrex human parkin cDNA construct and cloned into the EcoRI/HindIII restriction sites of the pGEX-KG vector (47). Constructs encoding sequences for the different human parkin domains (N1, N2, N3, C1, C2, C3) were generated by PCR using the piTrex parkin cDNA construct as a template and subcloned into the pGEX-KG vector as described above. For expression of parkin in mammalian tissue culture cells, human full-length parkin was amplified by PCR and subcloned into the EcoRI/XbaI restriction sites of the pCMV5-SV40-hGH vector (48). Point-mutated constructs were generated using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. The entire coding sequences of all constructs used in this study were verified by DNA sequencing. The sequences of all primers used in the present study are available upon author's request.
###end p 42
###begin title 43
Protein purification
###end title 43
###begin p 44
###xml 108 124 108 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C49">49</xref>
###xml 314 317 308 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 412 413 400 401 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 478 479 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 619 620 595 596 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 630 631 606 607 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 899 900 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1043 1044 991 992 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1057 1058 1005 1006 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1331 1332 1269 1270 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1354 1355 1292 1293 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1367 1368 1305 1306 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1373 1374 1311 1312 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1672 1673 1601 1602 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 108 129 <span type="species:ncbi:511693">Escherichia coli BL21</span>
###xml 1539 1545 <span type="species:ncbi:9913">bovine</span>
All recombinant proteins were expressed as N-terminally tagged glutathione S-transferase fusion proteins in Escherichia coli BL21 DE3 cells and purified essentially as described (49) with minor modifications as outlined below. A 5 ml overnight culture of cells was diluted 200-fold and grown at 37degreesC to an OD600 of around 0.6. Cells were incubated at 16degreesC for 15 min, followed by induction with 0.1 mm IPTG for 16-20 h at 16degreesC. Bacteria were pelleted at 10 000g for 10 min at 4degreesC, and the cell pellet resuspended in 12 ml (per liter culture) of resuspension buffer (PBS containing 1% TX-100, 1 mm PMSF, 1 mm DTT, 50 microg/ml RNAse, 50 microg/ml DNAse and 100 microg/ml lysozyme). The cell resuspension was incubated for 30 min at 4degreesC on a rotary shaker, followed by three sonication pulses (30 s each, separated by 30 s intervals) on ice. Upon centrifugation at 16 000g for 20 min at 4degreesC, the soluble fraction was filtered through a 0.22 microm filter and diluted with 6 ml of PBS containing 1% TX-100, 1 mm PMSF and 1 mm DTT (per liter of culture). Proteins were bound to glutathione Sepharose beads (Pharmacia) (750 microl of packed beads per liter of culture) for 2 h at 4degreesC. Beads were washed two times in PBS/1% TX-100, two times in PBS and two times in thrombin elution buffer (50 mm Tris-HCl, pH 8, 150 mm NaCl, 2.5 mm CaCl2, 0.1% (v/v) beta-mercaptoethanol). Pelleted beads were resuspended to a 50% slurry with thrombin elution buffer, and protein eluted with 50 units of thrombin (from bovine plasma; Sigma) per liter of culture for 1 h at 4degreesC with shaking. Purified proteins were dialyzed into PBS containing 1 mm DTT for 1 h at 4degreesC and small aliquots of recombinant parkin proteins were frozen at -20degreesC and only thawed up once. Protein concentration was determined by the BCA assay (Pierce) according to the manufacturer's instructions. Protein purity of all protein preparations was determined by Coomassie Blue staining, and in most cases was around 80-90%. In most cases, enzymatic activity of recombinant full-length parkin was assayed by autoubiquitylation reactions (see below) before the protein was used in other assays.
###end p 44
###begin title 45
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro phosphorylation assays
###end title 45
###begin p 46
###xml 119 127 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 334 335 326 327 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 349 350 341 342 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 360 361 352 353 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 366 367 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 546 547 538 539 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 580 581 568 569 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 776 777 760 761 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 792 793 776 777 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 803 804 787 788 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 809 810 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1002 1003 986 987 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1018 1019 1002 1003 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1024 1025 1008 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1249 1250 1216 1217 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1272 1273 1239 1240 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1302 1303 1266 1267 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1308 1309 1272 1273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1314 1315 1278 1279 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1334 1335 1294 1295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1337 1338 1297 1298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1496 1497 1452 1453 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1517 1518 1473 1474 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1534 1535 1490 1491 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1545 1546 1501 1502 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1558 1559 1514 1515 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1564 1565 1520 1521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1570 1571 1526 1527 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1724 1726 1668 1670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1901 1902 1839 1840 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1925 1926 1863 1864 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1931 1932 1869 1870 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1937 1938 1875 1876 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1949 1950 1887 1888 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2002 2003 1932 1933 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2008 2009 1938 1939 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2307 2308 2229 2230 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2341 2342 2259 2260 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 266 269 <span type="species:ncbi:10116">rat</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
###xml 710 715 <span type="species:ncbi:9606">human</span>
###xml 948 954 <span type="species:ncbi:10090">murine</span>
###xml 1062 1068 <span type="species:ncbi:9913">bovine</span>
###xml 1189 1194 <span type="species:ncbi:9606">human</span>
###xml 1367 1372 <span type="species:ncbi:9606">human</span>
###xml 1658 1664 <span type="species:ncbi:9913">bovine</span>
###xml 1801 1804 <span type="species:ncbi:10116">rat</span>
###xml 2132 2138 <span type="species:ncbi:9913">bovine</span>
###xml 2266 2271 <span type="species:ncbi:9606">human</span>
###xml 2381 2386 <span type="species:ncbi:10090">mouse</span>
Various recombinant wild-type and point-mutated full-length and truncated parkin proteins (1 microg) were subjected to in vitro phosphorylation reactions using buffer and enzyme conditions as outlined below. Phosphorylation by casein kinase I (0.5 units recombinant rat casein kinase Idelta; New England Biolabs) was performed in 50 mm Tris-HCl, 5 mm DTT, 10 mm MgCl2, pH 7.5, using 20 ng casein as a positive control. Phosphorylation by cyclin-dependent protein kinase 5 (cdk5) (20 ng of human full-length cdk5/p25; Upstate) was performed in 8 mm MOPS/NaOH, 0.2 microM EDTA, 10 mm Mg-acetate, pH 7.0, using 500 ng of histone H1 as a positive control. Phosphorylation by casein kinase II (1 microg recombinant human casein kinase II; New England Biolabs) was performed in 20 mm Tris-HCl, 50 mm KCl, 10 mm MgCl2, pH 7.5, using 20 ng of casein as a positive control. Phosphorylation by cAMP-dependent protein kinase A (PKA) (2.5 units of recombinant murine PKA; New England Biolabs) was performed in 50 mm Tris-HCl, 10 mm MgCl2, pH 7.5, using 1 microg of purified bovine synapsin I as a positive control. Phosphorylation by glycogen synthase kinase 3beta (GSK3beta) (1 microg of recombinant human his-tagged GSK3beta; Calbiochem) was performed in 25 mm Tris-HCl, pH 7.5, 5 mm beta-glycerolphosphate, 12 mm MgCl2, 2 mm DTT, 100 microM Na3VO4 using 100 ng of recombinant human tau protein (Calbiochem) as a positive control. Phosphorylation by 1 microg of protein kinase C (PKC) was performed in 50 mm HEPES, pH 7.4, 10 mm Mg-acetate, 1 mm EGTA, 1 mm EDTA, 1.5 mm CaCl2, 1 mm DTT, 50 microg/ml phosphatidylserine and 4 microg/ml diacylglycerol using 1 microg of bovine synapsin I as a positive control. For phosphorylation by Ca2+/calmodulin-dependent protein kinase II (CaMKII), 2.5 units of recombinant rat CaMKII (New England Biolabs) were activated for 10 min at 30degreesC in a buffer containing 50 mm Tris-HCl, pH 7.5, 10 mm MgCl2, 2 mm DTT, 0.1 mm EDTA, 100 microM ATP, 1.2 microM calmodulin and 2 mm CaCl2. One microgram of recombinant parkin was diluted in the same buffer and supplemented with 200 microM ATP, and 1 microg of bovine synapsin I served as a positive control. Phosphorylation by apoptosis signal-regulating kinase 1 (ASK1) (150 ng or recombinant human ASK1; Upstate) was performed in 8 mm MOPS/NaOH, 0.2 microM EDTA, 10 mm Mg-acetate, pH 7.0, using 1 microg of mouse myelin basic protein (MBP) (Sigma) as a positive control.
###end p 46
###begin p 47
###xml 162 163 154 155 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 194 196 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 669 671 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Unless otherwise stated, all reactions were carried out in a final volume of 40 microl and were initiated by the addition of ATP (final concentration of 100 microm) with trace amounts of [gamma-32P]ATP (GEHealthcare, specific activity 150 mCi/ml). After 30 min at 30degreesC with shaking (450 rpm), reactions were terminated by the addition of 0.2 volumes of 5x sample buffer and boiling for 5 min at 95degreesC. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% polyacrylamide gels (or 12.5% gels for assays containing N1-parkin or C3-parkin domains), followed by staining with Coomassie blue dye. Incorporation of 32P was quantified using a PhosphorImager (Molecular Dynamics) and corrected for background values. Differences in protein amounts were quantified on Coomassie-stained gels using QuantityOne (Bio-Rad) and corrected for background values, and radioactivity values were corrected for differences in protein loading.
###end p 47
###begin title 48
Autoubiquitylation reactions
###end title 48
###begin p 49
###xml 262 263 250 251 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 285 286 273 274 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 295 296 283 284 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 308 309 296 297 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 314 315 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Recombinant full-length parkin (1 microg) was incubated with 80-150 ng of E1 enzyme (His-E1, Biomol), 2 microg of E2 enzyme (His-UbcH7, Biomol) and 5 microg of ubiquitin (Sigma), or lysine-less or methylated ubiquitin (BostonBiochem), in a buffer containing 50 mm Tris-HCl, pH 7.4, 2 mm ATP, 1 mm DTT and 5 mm MgCl2. The reactions were conducted at 30degreesC for 90 min with shaking (450 rpm) and terminated by adding 0.2 volumes of 5x sample buffer and heating for 5 min at 95degreesC. Samples were resolved in 7.5% SDS-PAGE gels, followed by immunoblotting using a monoclonal anti-ubiquitin antibody (clone 6C1, Sigma) at 1:1000 dilution overnight at 4degreesC, and equal amount of protein loading was assured by immunoblotting samples independently with an anti-parkin antibody (844) at 1:1000 dilution overnight at 4degreesC.
###end p 49
###begin title 50
Generation of anti-parkin and anti-phospho-parkin antibodies
###end title 50
###begin p 51
###xml 155 162 <span type="species:ncbi:9986">rabbits</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 533 538 <span type="species:ncbi:9606">human</span>
Antibodies against parkin and phospho-parkin were generated in collaboration with PhosphoSolutions, Aurora, CO, USA. Briefly, antibodies were generated in rabbits against human parkin (around amino acids 400) (844) and against chemically phosphorylated S101 (EREPQS(phospho)LTRVDL) and S378 (GEGECS(phospho)AVFEAS) peptides. Phospho-state-specific antibodies were affinity-purified via sequential chromatography on phospho- and dephospho-peptide affinity columns. The p-Ser101 antibody was generally used to detect phospho-parkin in human brain extracts, whereas the p-Ser378 antibody was preferentially used to detect phospho-parkin in transfected HEK293 cell extracts.
###end p 51
###begin title 52
Cell culture, transfection and cell lysis
###end title 52
###begin p 53
###xml 77 78 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 141 142 135 136 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 363 364 357 358 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 219 225 <span type="species:ncbi:9913">bovine</span>
HEK293T cells were cultured in 100-mm dishes and grown at 37degreesC in 5% CO2 in growth medium (Dulbecco's modified Eagle's medium) with 4 mm glutamine and non-essential amino acids (Sigma), 10% heat-inactivated fetal bovine serum (Invitrogen), penicillin (100 units/ml) and streptomycin (100 units/ml). Confluent cells were harvested using 0.05% trypsin, 0.02 mm EDTA in PBS and subcultured at a ratio of 1:4 to 1:6. Cells at 50-60% confluency were transfected using 8 microg of plasmid of interest and 80 microl of PolyFect transfection reagent (Qiagen) per 100 mm dish according to the manufacturer's specifications for 4 h in growth medium, followed by addition of a fresh medium.
###end p 53
###begin p 54
###xml 139 140 135 136 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 225 226 217 218 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 387 388 375 376 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 586 587 570 571 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 679 680 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 916 917 892 893 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1155 1156 1131 1132 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1166 1167 1142 1143 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1170 1171 1146 1147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1173 1174 1149 1150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1182 1183 1158 1159 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
For preparation of extracts, cells were collected 48 h after transfection. Prior to collection, transfected cells were treated with 1 microm roscovitine (Calbiochem) for 12 h to inhibit endogenous cdk5 activity, with 50 microm IC261 (3-[(2,4,6-trimethoxyphenyl)methylidenyl]indolin-2-one) (Calbiochem) for either 3 or 12 h to inhibit endogenous casein kinase I activity, or with 35 microm D4476 for 12 h to inhibit endogenous casein kinase I activity. Cell viability was assessed by visual inspection as well as by Trypan blue exclusion assays. Although treatment of cells with 50 microm IC261 for 12 h caused a slight decrease in cell viability (by 3.6 +/- 1.6%, mean+/-S.E.M., n = 3), treatment of cells with IC261 for 3 h, or treatment of cells with any other kinase inhibitor analyzed in the present study did not display any effect upon cell viability. Where indicated, cells were further treated with 0.5 microm okadaic acid (Alomone Labs) for 1 h prior to processing to inhibit endogenous phosphatase activity. Cells were rinsed once in ice-cold PBS followed by resuspension in 1-1.5 ml of lysis buffer per 100 mm dish (1% SDS in PBS containing 1 mm PMSF, 1 mm Na3VO4 and 5 mm NaF). Resuspended cells were incubated for 15 min at 4degreesC in a rotary shaker, sonicated twice (two pulses for 1 s each) and centrifuged at 13 500 rpm for 10 min at 4degreesC. Protein concentrations of supernatants were estimated using the BCA assay (Pierce), followed by the addition of 0.2 volumes of 5x sample buffer and boiling for 5 min at 95degreesC. Samples were directly analyzed on western blots, as freeze-thaws were found to abolish detection of phospho-parkin levels. Unless otherwise stated, 80-100 microg of total protein extracts were loaded per lane to ensure sensitive detection of phospho-parkin levels.
###end p 54
###begin p 55
###xml 332 333 322 323 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 357 358 347 348 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 370 371 360 361 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 376 377 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 431 432 417 418 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 442 443 428 429 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 446 447 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 449 450 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 458 459 444 445 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 639 640 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1155 1161 <span type="species:ncbi:9986">rabbit</span>
For sequential fractionation studies, cells were collected 72 h after transfection. Cells were rinsed once in ice-cold PBS, followed by resuspension in 4 ml ice-cold PBS and the cell suspension equally split into two tubes. After centrifugation for 5 min (1500 rpm, 4degreesC), pellets were resuspended in 400 microl of buffer (50 mm Tris-HCl, pH 8.0, 300 mm NaCl, 1.5 mm MgCl2, 2 microg/ml chymostatin, 100 units/ml aprotinin, 1 mm PMSF, 1 mm Na3VO4 and 5 mm NaF) either containing 1% SDS (total) or containing 1% Triton X-100. The latter tube was incubated for 10 min at 4degreesC on a rotary shaker, followed by centrifugation at 82 000g for 20 min at 4degreesC. The supernatant (Triton-soluble) was removed, and the pellet resuspended in 200 microl of buffer containing 1% SDS, followed by repetitive sonication to obtain complete solubilization (Triton-insoluble). Protein concentration was estimated by the BCA assay (Pierce), and 40 microg of the total and the Triton-soluble fractions and 20 microg of the Triton-insoluble fractions were resolved by SDS-PAGE and analyzed by means of Western blotting. Extracts were independently analyzed using a rabbit anti-actin antibody (Sigma, 1:100) to account for differences in protein loading.
###end p 55
###begin title 56
Immunocytochemistry
###end title 56
###begin p 57
###xml 427 428 415 416 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 450 451 438 439 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 459 460 447 448 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1260 1261 1242 1243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 758 762 <span type="species:ncbi:9925">goat</span>
###xml 909 915 <span type="species:ncbi:9986">rabbit</span>
###xml 1056 1060 <span type="species:ncbi:9925">goat</span>
###xml 1066 1072 <span type="species:ncbi:9986">rabbit</span>
HEK293T or HEK293T/17 cells were plated onto 6-well plates at 40% confluency and transfected the following day (60% confluency) using 2 microg of DNA and 20 microl of PolyFect transfection reagent according to the manufacturer's instructions. Transfected cells were re-plated the next day at a 1:2 or 1:3 ratio onto coverslips and processed for immunocytochemistry 2 days later. Where indicated, cells were treated with 5 microm MG-132 (carbobenzoxy-l-leucyl-l-leucinal) (Calbiochem) for 12 h to inhibit proteasome activity, which enhances aggresome formation. Cells were then fixed for 30 min at 37degreesC with 4% (w/v) paraformaldehyde in PBS. Cells were permeabilized in 0.5% Triton X-100 in PBS (3x5 min washes) and preincubated in blocking buffer (10% goat serum; Vector Laboratories) in 0.5% Triton X-100 in PBS for 1 h at room temperature, followed by exposure to primary antibody [1:1000, polyclonal rabbit anti-parkin (844)] diluted in blocking buffer for 1 h at room temperature. Cells were washed in 0.5% Triton X-100 in PBS and incubated with goat anti-rabbit AlexaFluor-488-conjugated secondary antibody (1:1000, Invitrogen), diluted in 0.5% Triton X-100 in PBS, for 1 h at room temperature, followed by washes in 0.5% Triton X-100 in PBS, PBS, H2O and a rinse in 70% ethanol. Fixed cells were mounted using mounting medium containing DAPI (Vector Laboratories) and visualized on a Zeiss microscope using a 40x or 100x oil-immersion objective. Using this technique, transfection levels were usually found to be around 60%.
###end p 57
###begin p 58
###xml 588 592 <span type="species:ncbi:9925">goat</span>
###xml 598 603 <span type="species:ncbi:10090">mouse</span>
To determine the percentage of transfected cells containing parkin inclusions, cells overexpressing parkin were scored to display either diffuse cytosolic or aggregate staining. In addition, cells displaying aggregates were scored to either display at least one large perinuclear parkin aggregate or only multiple small aggregates. These values were used to determine the percentage of cells with (at least one) large inclusion. Perinuclear aggregates were independently verified to be aggresomes by double-staining with a monoclonal anti-vimentin antibody (1:200, clone V9, Sigma) and a goat anti-mouse AlexaFluor-594-conjugated secondary antibody (1:1000, Invitrogen). For all determinations, between 250 and 1000 transfected cells were analyzed, and in all cases, additional analysis was performed by an observer blind to conditions. Cells were also examined using a Leica TCS-SP5 confocal microscope and Leica Applied Systems (LAS-AF) image acquisition software. Images were collected using single excitation for each wavelength separately and channels subsequently merged using Adobe Photoshop.
###end p 58
###begin title 59
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cases
###end title 59
###begin p 60
All PD cases had suffered from classical parkinsonism and none of them had apparent cognitive impairment or dementia. The postmortem delay between death and tissue processing was between 3 and 7.5 h. The pH of the brain was between 6.6 and 6.9 in all cases. One-half of the brain was immediately cut on coronal sections, 1 cm thick, frozen in dry ice and stored at -80degreesC until use.
###end p 60
###begin p 61
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C50">50</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C51">51</xref>
All sporadic PD cases were tested for the G2019S LRRK2 mutation (50) and were also tested for the c.255delA mutation in parkin (51) if their age at onset was before 55 years. None of the samples analyzed here were positive for either mutation.
###end p 61
###begin p 62
###xml 305 307 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C52">52</xref>
###xml 415 417 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C53">53</xref>
###xml 2010 2011 1982 1983 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2012 2013 1984 1985 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Variable phenotypes and mixed pathologies can be observed in a significant fraction of postmortem cases, such as the presence of Alzheimer's disease-associated lesions combined with alpha-synuclein pathology in diagnosed PD cases, implying possible molecular crosstalks in protein aggregation mechanisms (52). In addition, Lewy body pathology has been observed in around 10% of brains from normal elderly subjects (53). To assure that our control subjects do not display Lewy body pathology and that our PD subjects display alpha-synuclein pathology in the absence of Alzheimer disease (AD)-related lesions, all samples were subjected to an extensive neuropathological study. Analysis was carried out on de-waxed 4-mum-thick paraffin sections of the frontal (area 8), primary motor, primary sensory, parietal, temporal superior, temporal inferior, anterior gyrus cinguli, anterior insular, and primary and associative visual cortices; entorhinal cortex and hippocampus; caudate, putamen and globus pallidus; medial and posterior thalamus; subthalamus; Meynert nucleus; amygdala; midbrain (two levels), pons and bulb; and cerebellar cortex and dentate nucleus. The sections were stained with hematoxylin and eosin, Kluever Barrera and, for immunohistochemistry, to glial fibrillary acidic protein (Dako, 1:250), CD68 (Dako, 1:100), betaA-amyloid (Boehringer Mannhein, 1:50), tau AT8 (Innogenetics, 1:500), tau 4R and tau 3R (Upstate, 1:200 and 1:2000, respectively), phosphorylation-specific tau Thr181, Ser202, Ser214, Ser262, Ser396 and Ser422 (all Calbiochem, 1:100, except Thr181, 1:250), alphaB-crystallin (Abcam, 1:100), ubiquitin (Dako, 1:200), alpha-synuclein (Chemicon, 1:3000), phosphorylation-specific alpha-synuclein Ser129 (WAKO, 1:2000) and nitrated/oxidized alpha-synuclein (Zymed, 1:400). Following incubation with the primary antibody, the sections were incubated with EnVision+system peroxidase for 15 min at room temperature. The peroxidase reaction was visualized with diaminobenzidine and H2O2. In all cases, control of the immunostaining included omission of the primary antibody.
###end p 62
###begin p 63
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C54">54</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C55">55</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN407C56">56</xref>
Neuropathological characterization of PD was according to established criteria (54). All PD cases corresponded to stage 4 of Braak and Braak. This implies involvement of selected nuclei of the medulla oblongata, pons and midbrain, amygdala and nucleus basalis of Meynert. All cases showed marked loss of neurons in the substantia nigra pars compacta exceeding 60%, whereas moderate pathology occurred in the caudate and putamen. In no case did Lewy pathology involve the frontal cortex. No cases of dementia with Lewy bodies, according to the guidelines of the specialized international workshop (55,56), were included in the present series. AD-related pathology, including beta-amyloid plaques and neurofibrillary tangles, was absent in the present series. Control subjects showed absence of neurological symptoms, metabolic and vascular diseases, and the neuropathological study disclosed no abnormalities including lack of PD- and AD-related pathology.
###end p 63
###begin title 64
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tissues and sample preparation
###end title 64
###begin p 65
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 228 235 <span type="species:ncbi:9606">patient</span>
###xml 303 310 <span type="species:ncbi:9606">patient</span>
Freshly frozen brain samples from deceased human subjects were collected at autopsy following informed consent from the next of kin under a protocol approved by the local ethics committee. Brain regions from each control and PD patient analyzed included cortex, cerebellum and caudate. For all samples, patient age, gender, time to postmortem tissue collection and postmortem pathological analysis was known.
###end p 65
###begin p 66
###xml 99 100 95 96 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 110 111 106 107 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 114 115 110 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 117 118 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 126 127 122 123 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Small sections of frozen tissue blocks were added to 700 microl of lysis buffer (1% SDS in PBS, 1 mm PMSF, 1 mm Na3VO4 and 5 mm NaF) and lysed using a 7-ml Dounce homogenizer with a Teflon pestle. Lysis was performed by applying slow strokes during maximally one minute. For cerebellar samples, an additional two pulses of sonication (1 s each) were needed to fully solubilize the tissue. Homogenates were subsequently centrifuged for 10 min at 13'500 rpm at 4degreesC. Protein concentration of the supernatants was estimated using a BCA assay (Pierce), and 0.2 volumes of 5x sample buffer added to extracts and boiling for 5 min at 95degreesC. Care was taken to ensure extracts were highly concentrated (>5 mg/ml) such that phospho-parkin levels could be determined using mini-gels. As mentioned above for transfected tissue culture cell extracts, samples were directly analyzed on western blots, as repetitive freeze-thaws were found to abolish detection of phospho-parkin levels and 80-100 microg of total protein extracts were loaded per lane to ensure sensitive detection of phospho-parkin levels.
###end p 66
###begin title 67
Western blotting
###end title 67
###begin p 68
###xml 213 219 <span type="species:ncbi:9986">rabbit</span>
###xml 1003 1009 <span type="species:ncbi:9986">rabbit</span>
###xml 1051 1056 <span type="species:ncbi:10090">mouse</span>
Proteins were resolved by SDS-PAGE, transferred onto polyvinylidene difluoride membranes (Hybond, GEHealthcare) and probed with primary antibodies overnight at 4degreesC. The following antibodies were employed: a rabbit polyclonal anti-parkin antibody (1:1000 for cell and brain extracts, ab6177, Abcam), a custom-made anti-parkin antibody 844 (1:1000 for recombinant proteins), an anti-phospho-S101-parkin antibody (1:200 for cell extracts and brain extracts) an anti-phospho-S378-parkin antibody (1:500 for cell extracts; 1:5000 for recombinant proteins), anti-p35 (1:100, C-19, Santa Cruz Biotechnology), anti-cdk5 (1:400, DC17, Santa Cruz Biotechnology), anti-casein kinase Iepsilon (1:250, BD Transduction Laboratories), anti-casein kinase Ialpha (1:200, C19, Santa Cruz Biotechnology), anti-casein kinase Idelta (1:50, H60, Santa Cruz Biotechnology), anti-alpha-tubulin (1:5000, clone DM1A, Sigma) and anti-actin (1:100, Sigma). Membranes were washed and incubated with secondary antibodies [anti-rabbit HRP-conjugated antibody (1:2000) or anti-mouse HRP-conjugated antibody (1:2000) (Dako Cytomation)] for 90 min at room temperature, followed by detection using ECL reagents (Roche).
###end p 68
###begin title 69
Statistical analysis
###end title 69
###begin p 70
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Experiments were done the indicated amount of times, and the data were analyzed using a Student's paired t-test.
###end p 70
###begin title 71
FUNDING
###end title 71
###begin p 72
###xml 43 75 43 75 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fondo de Investigaci&#243;n Sanitaria</grant-sponsor>
###xml 77 89 77 89 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIS-PI040262</grant-num>
###xml 96 118 96 118 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fundaci&#243;n Ram&#243;n Areces</grant-sponsor>
###xml 127 145 127 145 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Junta de Andalucia</grant-sponsor>
This work was supported by grants from the Fondo de Investigacion Sanitaria (FIS-PI040262), the Fundacion Ramon Areces and the Junta de Andalucia. S.H. was supported by a Ramon y Cajal Fellowship. Funding to Pay the Open Access Charge was provided by a grant from the Spanish Ministry of Science and Innovation (BFU2007-63635).
###end p 72
###begin title 73
ACKNOWLEDGEMENTS
###end title 73
###begin p 74
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
We thank P. Robinson for providing a construct encoding for human parkin, PhosphoSolutions for generating phosphorylation-state-specific antibodies and C. Sune for providing HEK293T cells. We thank the patients and their families for tissue donations. We thank A. Delgado for previous technical assistance, and our various colleagues for providing additional reagents and helpful discussions.
###end p 74
###begin p 75
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 75
###begin title 76
REFERENCES
###end title 76
###begin article-title 77
Parkinson's disease: mechanisms and models
###end article-title 77
###begin article-title 78
Genetics of Parkinson disease: paradigm shifts and future prospects
###end article-title 78
###begin article-title 79
Parkinson's disease
###end article-title 79
###begin article-title 80
Lewy bodies
###end article-title 80
###begin article-title 81
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
###end article-title 81
###begin article-title 82
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
###end article-title 82
###begin article-title 83
Association between early-onset Parkinson's disease and mutations in the parkin gene
###end article-title 83
###begin article-title 84
Lewy bodies and parkinsonism in families with parkin mutations
###end article-title 84
###begin article-title 85
Lewy body Parkinson's disease in a large pedigree with 77 parkin mutation carriers
###end article-title 85
###begin article-title 86
An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene
###end article-title 86
###begin article-title 87
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Immunohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients
###end article-title 87
###begin article-title 88
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies
###end article-title 88
###begin article-title 89
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
###end article-title 89
###begin article-title 90
RING finger 1 mutations in parkin produce altered localization of the protein
###end article-title 90
###begin article-title 91
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin
###end article-title 91
###begin article-title 92
Biochemical analysis of Parkinson's disease-causing variants of parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity
###end article-title 92
###begin article-title 93
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function
###end article-title 93
###begin article-title 94
Dopamine covalently modifies and functionally inactivates parkin
###end article-title 94
###begin article-title 95
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function
###end article-title 95
###begin article-title 96
Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity
###end article-title 96
###begin article-title 97
The roles of kinases in familial Parkinson's disease
###end article-title 97
###begin article-title 98
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity
###end article-title 98
###begin article-title 99
Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation
###end article-title 99
###begin article-title 100
Crystal structure of a conformation-selective casein kinase-1 inhibitor
###end article-title 100
###begin article-title 101
The selectivity of protein kinase inhibitors: a further update
###end article-title 101
###begin article-title 102
D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a
###end article-title 102
###begin article-title 103
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
###end article-title 103
###begin article-title 104
Stages in the development of Parkinson's disease-related pathology
###end article-title 104
###begin article-title 105
###xml 63 68 <span type="species:ncbi:9606">human</span>
Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition
###end article-title 105
###begin article-title 106
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain
###end article-title 106
###begin article-title 107
###xml 89 92 <span type="species:ncbi:10116">rat</span>
The expression of cdk5, p35, p39 and cdk5 kinase activity in developing, adult, and aged rat brains
###end article-title 107
###begin article-title 108
Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs
###end article-title 108
###begin article-title 109
Parkin: a multipurpose neuroprotective agent?
###end article-title 109
###begin article-title 110
Conversion of p35 to p25 deregulates cdk5 activity and promotes neurodegeneration
###end article-title 110
###begin article-title 111
Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5
###end article-title 111
###begin article-title 112
p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease
###end article-title 112
###begin article-title 113
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease
###end article-title 113
###begin article-title 114
Neurotoxicity induces cleavage of p35 to p25 by calpain
###end article-title 114
###begin article-title 115
CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease
###end article-title 115
###begin article-title 116
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I
###end article-title 116
###begin article-title 117
The casein kinase 1 family: participation in multiple cellular processes in eukaryotes
###end article-title 117
###begin article-title 118
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 110 113 <span type="species:ncbi:10116">rat</span>
The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo
###end article-title 118
###begin article-title 119
Association of protein phosphatase 1 gamma 1 with spinophilin suppresses phosphatase activity in a Parkinson disease model
###end article-title 119
###begin article-title 120
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease
###end article-title 120
###begin article-title 121
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 132 135 <span type="species:ncbi:10116">rat</span>
rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease
###end article-title 121
###begin article-title 122
Assessing fetal nerve grafts in Parkinson's disease
###end article-title 122
###begin article-title 123
###xml 33 49 33 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 33 49 <span type="species:ncbi:562">Escherichia coli</span>
Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione-S-transferase
###end article-title 123
###begin article-title 124
A role for SNARE complex dimerization during neurosecretion
###end article-title 124
###begin article-title 125
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
###end article-title 125
###begin article-title 126
A common LRRK2 mutation in idiopathic Parkinson's disease
###end article-title 126
###begin article-title 127
Association between early-onset Parkinson's disease and mutations in the parkin gene
###end article-title 127
###begin article-title 128
Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia
###end article-title 128
###begin article-title 129
Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA)
###end article-title 129
###begin article-title 130
Parkinson's disease
###end article-title 130
###begin article-title 131
Dementia with Lewy bodies
###end article-title 131
###begin article-title 132
Dementia with Lewy bodies
###end article-title 132

